Takeda keeps divestment spree rolling with $1.2B sale of diabetes meds to Japanese firm Teijin

After inking a slate of geography-specific product selloffs last year, Takeda has turned back to Japan.

Takeda locked up a deal to sell four Type 2 diabetes meds in Japan to local drugmaker Teijin Pharma for 133 billion Japanese yen ($1.2 billion), freeing up the company to focus on its core businesses in gastroenterology, rare diseases, plasma-derived therapies, oncology and neuroscience.